![](/img/cover-not-exists.png)
An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial
Grigg, A, Butcher, B, Khodr, B, Bajel, A, Hertzberg, M, Patil, S, D'Souza, A B, Ganly, P, Ebeling, P, Wong, ELanguage:
english
Journal:
Bone Marrow Transplantation
DOI:
10.1038/bmt.2017.108
Date:
June, 2017
File:
PDF, 374 KB
english, 2017